Transition Therapeutics says Alzheimer's drug effective in sub-group
Oct 15 (Reuters) - Dug developer Transition Therapeutics Inc said detailed data analysis of a study of its experimental drug showed it would benefit a group of Alzheimer's patients.
The company said on Thursday its drug was significantly effective in treating patients with severe agitation and aggression. (Reporting by Vidya L Nathan in Bengaluru; Editing by Don Sebastian)
© Thomson Reuters 2017 All rights reserved.